The positive outcomes of some of the rare candidates during the developmental stage by key players, such as Actimed Therapeutics (ACM-001), Aveo Oncology (AV-380), Pfizer (PF 06946860), Incyte (Jakafi), Extend Biosciences (EXT418) and others hold the potential to create a significant positive shift in cancer cachexia market size and the treatmetn outlook.
DelveInsight’s “Cancer Cachexia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Cancer Cachexia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Cancer Cachexia market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Cancer Cachexia: An Overview
Cancer cachexia is a wasting syndrome that is characterized by weight loss, anorexia (loss of desire to eat), asthenia, and anemia. The pathogenicity of this syndrome is multifactorial due to a complex interaction of tumor and host factors. It occurs in patients with advanced cancer, chronic obstructive pulmonary disease, chronic infection including AIDS and tuberculosis, chronic heart failure, and rheumatoid arthritis. However, the occurrence of cancer cachexia is high, especially in patients with advanced cancer, and this syndrome often remains underdiagnosed.
Cachexia is a complex metabolic multi-organ syndrome characterized by at least 5% of weight loss, muscle and adipose tissue wasting, and inflammation, as it taps into other sources of energy, namely skeletal muscle and adipose tissue, when the body senses a lack of nutrition. Cachexia is characterized by increased pro-inflammatory factors and adversely affects the patient’s ability to fight against infection and withstand treatment by chemotherapy and radiotherapy. It is often associated with an elevated basal metabolic rate, despite a decrease in physical activity and total energy expenditure. Muscle atrophy results from a decrease in protein synthesis, an increase in protein degradation, or a combination of both. This results in a decreased quality of life and reduced survival rates.
Cancer Cachexia Market Key Facts
Several secondary studies suggest that the overall incidence of cachexia is high, and in industrialized countries, such as North America, Europe, and Japan, it is growing. It is currently estimated that cachexia affects approximately 9 million patients, which is about 1% of all patients with any disease.
As per a Japanese study conducted by Aoyagi et al., “Cancer cachexia, mechanism and treatment,” cachexia occurs in the majority of terminal cancer patients and is responsible for the death of 22% of cancer patients.
Cancer Cachexia Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Cancer Cachexia market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Cancer Cachexia market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Cancer Cachexia Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Cancer Cachexia Epidemiology, Segmented as –
Incident/Prevalent Cases of Cancer Cachexia in the 7MM (2019–2032)
Diagnosed Cases of Cancer Cachexia in the 7MM (2019-2032)
Treatable Cases of Cancer Cachexia in the 7MM (2019-2032)
Cancer Cachexia Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Cancer Cachexia market or expected to be launched during the study period. The analysis covers the Cancer Cachexia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Cancer Cachexia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Cancer Cachexia Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/cancer-cachexia-cc-market-insights
Cancer Cachexia Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Cancer Cachexia. Currently, AEterna Zentaris is leading the therapeutics market with its Cancer Cachexia drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Cancer Cachexia Therapeutics Market Include:
Actimed Therapeutics
AEterna Zentaris
Aphios Corporation
Artelo BIOSCIENCES
Aveo Oncology
Caelus Health
Cannabics Pharmaceuticals
Helsinn Therapeutics
Ildong Pharmaceutical
Incyte Corporation
Janssen Pharmaceutical
NGM Biopharmaceuticals
Ono Pharmaceutical
Pfizer
Smartfish AS
Tetra Bio-Pharma
XBiotech
And Many Others
Cancer Cachexia Emerging and Marketed Drugs Covered in the Report Include:
ACM-001 : Actimed Therapeutics
Adlumiz: Ono Pharmaceutical
AV-380: Aveo Oncology
Macimorelin: AEterna Zentaris
PF- 06946860: Pfizer
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Cancer Cachexia Competitive Intelligence Analysis
4. Cancer Cachexia Market Overview at a Glance
5. Cancer Cachexia Disease Background and Overview
6. Cancer Cachexia Patient Journey
7. Cancer Cachexia Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Cancer Cachexia Treatment Algorithm, Current Treatment, and Medical Practices
9. Cancer Cachexia Unmet Needs
10. Key Endpoints of Cancer Cachexia Treatment
11. Cancer Cachexia Marketed Products
12. Cancer Cachexia Emerging Drugs and Latest Therapeutic Advances
13. Cancer Cachexia Seven Major Market Analysis
14. Attribute Analysis
15. Cancer Cachexia Market Outlook (In US, EU5, and Japan)
16. Cancer Cachexia Access and Reimbursement Overview
17. KOL Views on the Cancer Cachexia Market
18. Cancer Cachexia Market Drivers
19. Cancer Cachexia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification Strategies
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
